Navigation Links
Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts
Date:12/1/2011

‐progressive increases in serum creatinine, increased transaminases, abdominal distension, constipation, dyspepsia, proteinuria, and headache. 

Please visit www.exjade.com for more information.

About INC424 (ruxolitinib)
INC424 (ruxolitinib) is an oral inhibitor of the JAK1 and JAK2 tyrosine kinases. INC424 is being investigated in primary myelofibrosis as well as post-polycythemia vera  myelofibrosis (PPV-MF) and post-essential thrombocythemia myelofibrosis (PET-MF). INC424 is also being investigated in clinical trials for the treatment of polycythemia vera (PV).

Novartis licensed INC424 from Incyte for development and potential commercialization outside the US. Incyte has retained rights for the development and potential commercialization of INC424 in the US. Both the US Food and Drug Administration and the European Medicines Agency have granted INC424 orphan drug status for myelofibrosis.

Disclaimer
The foregoing release contains forward-looking statements that can be identified by terminology such as "will," "goal," "potential," or similar expressions, or by express or implied discussions regarding potential new indications or labeling, or potential marketing approvals for Novartis Oncology products, or regarding potential future revenues from such products. You should not place undue reliance on these statements.  Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any additional indications or labeling will be approved for any existing Novartis Oncology products, or that any new Novartis Oncology products will be approved for sale in any market, or at any particul
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related biology technology :

1. Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
2. Genentech and Novartis Remain Image Leaders in Oncology and Hematology
3. FDA Advisory Committee Recommends US Approval of Novartis Once-daily Bronchodilator QAB149 for COPD
4. Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows
5. With the Recent Launch of Novartiss Gilenya, Extavia is Pushed Into the Background of Multiple Sclerosis Treatment One Year After its Launch
6. VIDEO from Novartis Available on thenewsmarket.com: Novartis Presents Data about Tasigna in Treatment of Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia
7. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
8. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
9. Novartis Class Awarded $250 Million in Punitive Damages
10. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
11. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Lyme Research Alliance (LRA), the nation’s ... universities, today announced the awarding of seven grants worth ... cure for Lyme and other tick-borne diseases. , ... its history—over 20 grant proposals—a 100 percent increase from ... receive so many solid applications from talented scientists this ...
(Date:9/30/2014)... September 30, 2014 Rainbow Scientific, ... research products, recently opened an online store to ... culture product lines developed and manufactured by Biological ... store include Biological Industries’ Nutristem® serum-free, xeno-free reagents ... embryonic stem cell (hESC) culture. , The ...
(Date:9/30/2014)... 2014 UFP Technologies, a producer ... has recently introduced a custom insulated shipping container ... The new insulated shipper solves the issue of ... UFP Technologies’ BioShell is a universal storage container ... handling and shipping. The insulated shipper keeps frozen ...
(Date:9/30/2014)... Canada (PRWEB) September 30, 2014 Back in ... on 500 square feet. per employee, which included space for ... back then.” says Jeff Howell, partner at Nidea Corporate ... firm in Toronto. “By the year 2000, however, 250 ... now seeing that number come down to 175 to 225 ...
Breaking Biology Technology:Lyme Research Alliance Awards Nearly $600,000 in New Grants 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 3Lyme Research Alliance Awards Nearly $600,000 in New Grants 4Rainbow Scientific, Inc. opens online store for state-of-the-art stem cell culture and cytogenetic reagents 2UFP Technologies Introduces Insulated Shipping Container For Bulk Drug Transportation 2UFP Technologies Introduces Insulated Shipping Container For Bulk Drug Transportation 3ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 3
... Alba Therapeutics Corporation today,announced that its Investigational ... of endogenous insulin production capacity in new-onset,type 1 ... deliberation period,by the U.S. Food and Drug Administration ... study in 2008 while focusing the majority,of its ...
... will review common U.S. laws on research and process labs ... offer practical ... in association with Lab Manager Magazine, will present a Web,conference ... EST. The online conference will review common U.S. federal laws,pertaining ...
... SAN CARLOS, Calif., Sept. 5 NeurogesX, Inc.,(Nasdaq: ... developing novel,pain management therapies, announced today the appointment ... directors. Since May 2006, Mr. Peacock,has been a ... Prior to joining SV Life Sciences, Mr. Peacock ...
Cached Biology Technology:Alba Therapeutics Announces IND for Beta Cell Preservation in Type 1 Diabetes Using AT-1001 2Sigma-Aldrich and Lab Manager Magazine Present Webinar On Laboratory Environmental, Health and Safety Compliance Strategies 2Sigma-Aldrich and Lab Manager Magazine Present Webinar On Laboratory Environmental, Health and Safety Compliance Strategies 3NeurogesX Appoints New Director to the Board 2NeurogesX Appoints New Director to the Board 3
(Date:9/29/2014)... Energy Joint Genome Institute (DOE JGI), a DOE ... 32 new projects have been selected for the ... lakes to Caribbean waters, and from plant root ... in forested watersheds, the CSP 2015 projects portfolio ... be extracted. , "These projects catalyze JGI,s ...
(Date:9/29/2014)... anti-tumour activity in patients with advanced BRAF V600E ... progressed after chemotherapy, according to phase II data ... Spain. , "Reports of lung cancers bearing ... these mutations may be associated with increased sensitivity ... Dr David Planchard, pulmonary oncologist at the Gustav-Roussy ...
(Date:9/29/2014)... is here, and that means beer. And ... cold one, taking that first sip and ... reacted to form compounds that cause an ... why beers get skunky, and what you ... going bad. Learn all about it at ...
Breaking Biology News(10 mins):2015 DOE JGI's science portfolio delves deeper into the Earth's data mine 22015 DOE JGI's science portfolio delves deeper into the Earth's data mine 32015 DOE JGI's science portfolio delves deeper into the Earth's data mine 42015 DOE JGI's science portfolio delves deeper into the Earth's data mine 52015 DOE JGI's science portfolio delves deeper into the Earth's data mine 62015 DOE JGI's science portfolio delves deeper into the Earth's data mine 72015 DOE JGI's science portfolio delves deeper into the Earth's data mine 82015 DOE JGI's science portfolio delves deeper into the Earth's data mine 9Promising results shown with targeted approaches in subsets of non-small cell lung cancer 2Promising results shown with targeted approaches in subsets of non-small cell lung cancer 3
... steps have public officials in your state or community taken ... who are obese has tripled in just 35 years. Local ... it either easy or hard for families to find fresh ... and be physically active. LOCAL GOVERNMENT ACTIONS TO PREVENT CHILDHOOD ...
... at Virginia Tech, Harvard and Drexel finish studying the locomotion ... has a few new ways to increase his own world-breaking ... to maneuver in tight places, or to hover in one ... has researchers wondering if they can create smarter materials that ...
... Zurich, Switzerland, August 18, 2009 / b3c newswire ... that, following the successful completion of key research ... disease has advanced into preclinical development, triggering milestone ... (NASDAQ: BIIB). Neurimmune partnered with Biogen Idec for ...
Cached Biology News:Tackling childhood obesity at the local level -- IOM report releases Sept. 1 2NSF Emerging Frontiers' program supports development of smart materials based on study of fish 2NSF Emerging Frontiers' program supports development of smart materials based on study of fish 3Neurimmune Therapeutics Announces Advancement of Alzheimers Program into Preclinical Development 2Neurimmune Therapeutics Announces Advancement of Alzheimers Program into Preclinical Development 3
Identify and characterize Phosphoinositide (PI(4,5)P2) binding...
... micro test tubes are used to store ... tubes have uniform walls for uniform heat ... O-ring screw caps. The O-rings are made ... operating range from -55 to 150 degrees ...
... Sac-Cel (Second Antibody Coated CELlulose) was ... Diagnostics of Dartford, Kent, one of the ... world. IDS acquired the product range in ... and clinical biochemists developing their own "in ...
Determine relative degree of protein binding to phosphoinositides...
Biology Products: